

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Larotrectinib for treating NTRK fusion-positive advanced solid tumours  
[ID1299]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation a potential equalities issue was raised. The use of larotrectinib may be restricted to people with rare tumour types where NTRK fusion mutation are more common in the first instance, because testing for larotrectinib is not yet established in the NHS. This was considered a function of the clinical condition and not the technology under assessment.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The potential equality issue identified was considered a function of the clinical condition and not the technology under assessment and therefore is not considered an equalities issue.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made to the draft scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?
No additional stakeholders identified.

**Approved by Associate Director (name):** Linda Landells

**Date:** 12 March 2019